Invicta Medical

Restera is pioneering a disruptive, minimally invasive neurostimulation therapy for Obstructive Sleep Apnea (OSA), a condition affecting an estimated one billion people globally. The company's core innovation is a miniature implant placed via needle injection under ultrasound guidance, targeting novel neural structures like the hypoglossal nerve and ansa cervicalis to open the airway. With a strong clinical and scientific advisory board, over 50 patents, and multiple successful proof-of-concept human studies, Restera is advancing a solution aimed at overcoming the severe compliance issues plaguing the dominant CPAP market. The company is positioned to address a massive, underserved market with significant economic burden.

Minimally invasive, injectable neurostimulation platform targeting novel neural structures (hypoglossal nerve branches, ansa cervicalis) to restore upper airway patency in OSA. Utilizes ultrasound-guided needle delivery for outpatient implantation.

Primary competition includes CPAP (ResMed, Philips) and surgically implanted hypoglossal nerve stimulators (Inspire Medical Systems). Restera's key differentiator is its minimally invasive, injectable approach, aiming to offer efficacy comparable to surgical implants with a much simpler procedure. It also competes with other emerging neurostimulation and device-based therapies in development.